

**DOCKET NO.: ISIS0052-100 (ISPH-0622)**  
**SERIAL NO.: 10/005,344**

**PATENT**  
**FILED: December 4, 2001**

**In the Claims:**

The present listing of claims will replace all prior versions and listings of claims in the application.

Please cancel claim 9.

Please cancel claims 12-50 without prejudice to their presentation in another application, as being drawn to non-elected inventions.

Please amend claim 1 and add new claims 51-59 as follows.

---

Claim 1 (currently amended) An antisense compound 8 to 30 nucleobases in length targeted to the 5' untranslated region, ~~coding region, intron:exon junction, intron region, exon region, translation termination codon region or 3' untranslated region of a nucleic acid molecule encoding mdm2, wherein said antisense compound modulates the expression of mdm2.~~

Claim 2 (original) The antisense compound of claim 1 wherein said antisense compound inhibits the expression of human mdm2.

*(B)*  
Claim 3 (original) The antisense compound of claim 1 which is an antisense oligonucleotide.

Claim 4 (canceled)

Claim 5 (currently amended) The antisense compound of claim 2 wherein the nucleic acid molecule encoding mdm2 is the S-mdm2 transcript, and wherein the antisense compound which is targeted to the 5' untranslated region of the S-mdm2 transcript.

Claim 6 (original) The antisense compound of claim 1 which contains at least one phosphorothioate intersugar linkage.

**DOCKET NO.: ISIS0052-100 (ISPH-0622)**  
**SERIAL NO.: 10/005,344**

**PATENT**  
**FILED: December 4, 2001**

**Claim 7 (original)** The antisense compound of claim 1 which has at least one 2'-O-methoxyethyl modification.

**Claim 8 (original)** The antisense compound of claim 1 which contains at least one 5-methyl cytidine.

**Claim 9 (canceled)**

**Claim 10 (original)** A pharmaceutical composition comprising the antisense compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

**Claim 11 (original)** The pharmaceutical composition of claim 10 wherein said pharmaceutically acceptable carrier or diluent further comprises a lipid or liposome.

**Claims 12-50 (cancelled)**

**Claim 51 (new)** The antisense compound of claim 7 wherein at least one 2'-O-methoxyethyl modification is in a cytidine.

**Claim 52 (new)** The antisense compound of claim 51 in which every 2'-O-methoxyethyl modified cytidine is a 5-methyl cytidine.

**Claim 53 (new)** An antisense compound 8 to 30 nucleobases in length targeted to the coding region or exon region of a nucleic acid molecule encoding mdm2, wherein said antisense compound is a chimeric phosphorothioate oligonucleotide comprising 2'-methoxyethyl wings and a deoxy gap, and wherein said antisense compound inhibits mdm2 expression by at least 60%.

**Claim 54 (new)** The antisense compound of claim 53 wherein said antisense compound inhibits the expression of human mdm2.

**DOCKET NO.: ISIS0052-100 (ISPH-0622)**  
**SERIAL NO.: 10/005,344**

**PATENT**  
**FILED: December 4, 2001**

Claim 55 (new) The antisense compound of claim 53 which comprises at least one 5-methyl cytidine.

Claim 56 (new) The antisense compound of claim 53 wherein at least one 2'-methoxyethyl modification is in a cytidine.

*(3)*  
Claim 57 (new) The antisense compound of claim 56 in which every 2'-methoxyethyl modified cytidine is a 5-methyl cytidine.

Claim 58 (original) A pharmaceutical composition comprising the antisense compound of claim 53 and a pharmaceutically acceptable carrier or diluent.

Claim 59 (original) The pharmaceutical composition of claim 58 wherein said pharmaceutically acceptable carrier or diluent further comprises a lipid or liposome.